|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,552,000 |
Market
Cap: |
2.30(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.07 - $59.1 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 8 |
Insider 3/6 Months : 8.6 |
|
Guru Rank Number : 538 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,700 |
7,700 |
7,700 |
Total Buy Value |
$0 |
$198,736 |
$198,736 |
$198,736 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
8,105 |
52,172 |
114,858 |
280,340 |
Total Sell Value |
$209,105 |
$1,447,501 |
$4,819,149 |
$12,887,777 |
Total People Sold |
6 |
8 |
10 |
15 |
Total Sell Transactions |
9 |
26 |
35 |
88 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2024-04-19 |
4 |
S |
$24.89 |
$83,669 |
D/D |
(3,361) |
225,807 |
|
- |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2024-04-17 |
4 |
S |
$25.14 |
$32,851 |
D/D |
(1,307) |
229,168 |
|
-3% |
|
Pauwels Eric |
CHIEF EXECUTIVE OFFICER |
|
2024-04-17 |
4 |
S |
$25.14 |
$19,781 |
D/D |
(787) |
67,694 |
|
-3% |
|
Golden Lee Scott |
EVP & CHIEF MEDICAL OFFICER |
|
2024-04-02 |
4 |
S |
$28.37 |
$14,923 |
D/D |
(526) |
59,988 |
|
11% |
|
Utter Christine Marie |
SVP, CHIEF ACCOUNTING OFFICER |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,900 |
52,428 |
|
- |
|
Reeve Emma |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
11,200 |
|
- |
|
Gravier Pierre |
CHIEF FINANCIAL OFFICER |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,100 |
55,800 |
|
- |
|
Schmertzler Michael |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
123,266 |
|
- |
|
Steele Glenn Jr Md |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
14,500 |
|
- |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
I/I |
870 |
4,576 |
|
- |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
86,202 |
|
- |
|
Golden Lee Scott |
CHIEF MEDICAL OFFICER |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,600 |
60,514 |
|
- |
|
Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
230,475 |
|
- |
|
Young Alethia |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
13,067 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,200 |
92,389 |
|
- |
|
Bell William F. Jr. |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
10,333 |
|
- |
|
Zeldis Jerome B |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
14,500 |
|
- |
|
Smith Mary L. |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
13,813 |
|
- |
|
Southwell David P |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
14,500 |
|
- |
|
Jacobson Allan Steven |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
16,348 |
|
- |
|
Okey Stephanie |
|
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
9,867 |
|
- |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,300 |
68,481 |
|
- |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2024-01-30 |
4 |
S |
$27.25 |
$21,637 |
D/D |
(794) |
71,189 |
|
5% |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2024-01-30 |
4 |
S |
$27.25 |
$9,974 |
D/D |
(366) |
44,181 |
|
5% |
|
Utter Christine Marie |
SVP, CHIEF ACCOUNTING OFFICER |
|
2024-01-30 |
4 |
S |
$27.25 |
$8,666 |
D/D |
(318) |
35,528 |
|
5% |
|
564 Records found
|
|
Page 1 of 23 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|